We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
Cap. Flow
+$34M
Cap. Flow %
12.86%
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45

Top Buys

Rank Stock Value
1
DTM icon
DT Midstream
DTM
+$1.85M
2
DK icon
Delek US
DK
+$898K
3
SMG icon
ScottsMiracle-Gro
SMG
+$843K
4
VLO icon
Valero Energy
VLO
+$783K
5
FMC icon
FMC
FMC
+$709K

Top Sells

Rank Stock Value
1
COR
Coresite Realty Corporation
COR
+$1.67M
2
XLRN
Acceleron Pharma
XLRN
+$601K
3
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$448K
5
TVTX icon
Travere Therapeutics
TVTX
+$434K

Sector Composition

Rank Sector Weight
1 Real Estate 22.39%
2 Healthcare 18.38%
3 Energy 15.88%
4 Materials 14.07%
5 Utilities 13.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
376
DELISTED
Allakos
ALLK
$20K 0.01%
2,014
-326
-14% -$26.7K
ADVM
377
DELISTED
Adverum Biotechnologies
ADVM
– –
-5,777
Closed -$125K
ANVS icon
378
Annovis Bio
ANVS
$71.9M
– –
-2,387
Closed -$76K
APLT
379
DELISTED
Applied Therapeutics
APLT
– –
-8,790
Closed -$146K
ARDX icon
380
Ardelyx
ARDX
$1.26B
– –
-28,694
Closed -$38K
BDTX icon
381
Black Diamond Therapeutics
BDTX
$101M
– –
-16,600
Closed -$140K
BOLT icon
382
Bolt Biotherapeutics
BOLT
$7.72M
– –
-651
Closed -$165K
CARM
383
DELISTED
Carisma Therapeutics
CARM
– –
-2,501
Closed -$40K
CRDF icon
384
Cardiff Oncology
CRDF
$63.6M
– –
-25,770
Closed -$172K
DNTH icon
385
Dianthus Therapeutics
DNTH
$5.55B
– –
-1,169
Closed -$136K
ESPR
386
DELISTED
Esperion Therapeutics
ESPR
– –
-17,773
Closed -$214K
ETNB
387
DELISTED
89bio
ETNB
– –
-10,877
Closed -$213K
FBRX icon
388
Forte Biosciences
FBRX
$1.57B
– –
-209
Closed -$15K
IMTX icon
389
Immatics
IMTX
$1.19B
– –
-17,438
Closed -$227K
IRON icon
390
Disc Medicine
IRON
$2.85B
– –
-623
Closed -$76K
KPTI icon
391
Karyopharm Therapeutics
KPTI
$161M
– –
-2,958
Closed -$258K
KRRO icon
392
Korro Bio
KRRO
$151M
– –
-426
Closed -$150K
OMER icon
393
Omeros
OMER
$816M
– –
-29,436
Closed -$406K
RIGL icon
394
Rigel Pharmaceuticals
RIGL
$712M
– –
-10,466
Closed -$380K
SPRY icon
395
ARS Pharmaceuticals
SPRY
$563M
– –
-6,371
Closed -$64K
TARS icon
396
Tarsus Pharmaceuticals
TARS
$2.57B
– –
-6,008
Closed -$129K
WVE icon
397
Wave Life Sciences
WVE
$1.13B
– –
-29,090
Closed -$143K
XBIT icon
398
XBiotech
XBIT
$69.2M
– –
-14,424
Closed -$187K
TECX
399
Tectonic Therapeutic
TECX
$562M
– –
-1,854
Closed -$124K
SYRS
400
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-3,609
Closed -$161K
13 14 15
16
17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2021 Portfolio in Review

As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.

Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.

By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.

  • Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
  • Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
  • Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
  • Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
  • Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
  • Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
  • Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.